Regencell Bioscience Holdings Ltd. | Large-cap | Healthcare
$17.04
-2.07%
| Regencell Bioscience Stock Comparison:
Regencell Bioscience vs ZoetisRegencell Bioscience vs Haleon Plc - ADRRegencell Bioscience vs Elanco Animal HealthRegencell Bioscience vs Lantheus HoldingsRegencell Bioscience vs Alkermes plcRegencell Bioscience vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -4.7M
Net Income -4.4M

Balance Sheet Metrics

Total Assets 8.4M
Total Liabilities 219.5K
Shareholders Equity 8.2M
Debt to Equity 0.03

Cash Flow Metrics

Operating Cash Flow -3.9M
Free Cash Flow -4.0M

Revenue & Profitability Trend

Regencell Bioscience Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 0 0 0 0 0
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 4.7M 6.3M 7.6M 1.4M 812.4K
Operating Income -4.7M -6.3M -7.6M -1.4M -812.4K
Pre-tax Income -4.4M -6.1M -7.6M -1.3M -812.4K
Income Tax 0 0 0 0 0
Net Income -4.4M -6.1M -7.6M -1.3M -812.4K
EPS (Diluted) - -$0.45 -$0.58 -$0.11 -$0.06

Income Statement Trend

Regencell Bioscience Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 8.1M 11.6M 16.4M 66.8K 387.0K
Non-Current Assets 324.2K 1.0M 1.6M 273.3K 127.0K
Total Assets 8.4M 12.6M 18.0M 340.1K 514.0K
Liabilities
Current Liabilities 193.6K 606.9K 577.8K 4.3M 3.2M
Non-Current Liabilities 25.9K 25.4K 360.3K 0 0
Total Liabilities 219.5K 632.3K 938.0K 4.3M 3.2M
Equity
Total Shareholders Equity 8.2M 12.0M 17.1M -4.0M -2.7M

Balance Sheet Composition

Regencell Bioscience Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -4.4M -6.1M -7.6M -1.3M -812.4K
Operating Cash Flow -3.9M -4.9M -4.7M -1.3M -802.9K
Investing Activities
Capital Expenditures -5.4K -26.4K -780.9K 0 -117.8K
Investing Cash Flow 5.2M 59.0K -10.8M 0 -117.8K
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 102.3K 134.9K 22.4M 439.7K 988.1K
Free Cash Flow -4.0M -5.0M -6.0M -767.3K -844.4K

Cash Flow Trend

Regencell Bioscience Key Financial Ratios

Valuation Ratios

Price to Book 1,394.12

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -43.18%
Return on Assets -28.11%

Financial Health

Current Ratio 41.92
Debt to Equity 1.04
Beta 2.62

Per Share Data

EPS (TTM) -$0.01
Book Value per Share $0.02

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
rgc 18.5B - 1,394.12 -43.18% 0.00% 1.04
Zoetis 70.3B 28.34 15.12 52.09% 27.12% 145.63
Haleon Plc - ADR 47.2B 25.01 5.88 8.95% 12.84% 63.41
Elanco Animal Health 6.6B 17.80 1.04 6.01% 8.43% 69.18
Lantheus Holdings 5.6B 23.07 4.81 24.11% 16.55% 52.78
Alkermes plc 4.8B 13.93 3.19 25.71% 23.30% 4.90

Financial data is updated regularly. All figures are in the company's reporting currency.